TESARO shares should be bought on weakness, says RW Baird

theflyonthewall.com

RW Baird recommends TESARO shares be bought on weakness after two of three trials of rolapitant met their primary endpoints but missed their secondary endpoints. The firm notes that another trial of the drug is still ongoing and believes the opportunity for the drug is still intact after the data. RW Baird maintains an Outpeform rating and $57 target on TESARO.

View Comments (0)